GLP-1 (7-37)
Native GLP-1 active fragment representing the biologically active form of endogenous glucagon-like peptide-1. Essential reference compound for GLP-1 receptor pharmacology and mechanism of action studies.
GLP-1 (7-37) is an endogenous incretin hormone secreted by intestinal L-cells, playing a central role in glucose homeostasis. As one of the major bioactive forms, this 31-amino-acid peptide activates GLP-1 receptors (GLP-1R) to enhance glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and increase satiety. GLP-1 receptor agonists have become revolutionary therapeutics in the treatment of Type 2 diabetes and obesity.
| Parameter | Specification |
| CAS | 106612-94-6 |
| Molecular Formula | C₁₅₁H₂₂₈N₄₀O₄₇ |
| Molecular Weight | 3355.67 g/mol |
| Category | GLP-1/Metabolic |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | GLP-1 mechanism research, receptor pharmacology, native peptide comparison |
| CAS | 106612-94-6 |
|---|---|
| Applications | Diabetes Research, GLP-1 Analog Development, metabolic syndrome |
Related products
-
Semaglutide
CAS: 910463-68-2Applications: cardiovascular risk reduction, obesity management, Type 2 diabetes -
Lixisenatide
CAS: 320367-13-3Applications: postprandial glucose control, Short-acting GLP-1, Type 2 diabetes -
Retatrutide
CAS: 2381089-83-2Applications: Refractory diabetes, Severe obesity, Triple agonist, weight management -
Aviptadil
CAS: 40077-57-4Applications: Acute respiratory distress syndrome, ARDS, Lung protection, Pulmonary hypertension, VIP analog